Evidence map›Paper›PMID 41893787›Full record

ReviewVaccines2026

Vaccination in Oncology Patients: Evidence, Clinical Challenges, and Future Directions.

Alberto Giuseppe Agostara, Silvia Della Torre, Sara Di Bella, Michela Pelliccione, Paola Candido, Valeria Smiroldo, Laura Roazzi, Gabriele Ciarlo, Davide Toniolo, Francesca Zannier and 1 more

Abstract readReview
In one paragraph

Review in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Current Vaccination Principles and Practices in Adult Cancer Patients.Journal of clinical practice and research · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alberto Giuseppe AgostaraDepartment of Oncology, Ospedale G. Salvini-Rho-ASST Rhodense, Rho, 20017 Milan, Italy.ORCID 0000-0001-5646-7150
Silvia Della TorreDepartment of Oncology, Ospedale G. Salvini-Rho-ASST Rhodense, Rho, 20017 Milan, Italy.
Sara Di BellaDepartment of Oncology, Ospedale G. Salvini-Rho-ASST Rhodense, Rho, 20017 Milan, Italy.
Michela PelliccioneDepartment of Oncology, Ospedale G. Salvini-Rho-ASST Rhodense, Rho, 20017 Milan, Italy.
Paola CandidoDepartment of Oncology, Ospedale G. Salvini-Rho-ASST Rhodense, Rho, 20017 Milan, Italy.
Valeria SmiroldoDepartment of Oncology, Ospedale G. Salvini-Rho-ASST Rhodense, Rho, 20017 Milan, Italy.
Laura RoazziDepartment of Oncology and Hemato-Oncology, Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy.
Gabriele CiarloDepartment of Oncology and Hemato-Oncology, Grande Ospedale Metropolitano Niguarda, 20162 Milan, Italy.ORCID 0009-0006-4991-2002
Davide TonioloDepartment of Oncology, Ospedale G. Salvini-Rho-ASST Rhodense, Rho, 20017 Milan, Italy.
Francesca ZannierDepartment of Oncology, Ospedale G. Salvini-Rho-ASST Rhodense, Rho, 20017 Milan, Italy.
Roberto BollinaDepartment of Oncology, Ospedale G. Salvini-Rho-ASST Rhodense, Rho, 20017 Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This narrative review provides a comprehensive synthesis of patients with cancer disproportionately affected by vaccine-preventable infectious diseases due to malignancy-related immune dysfunction and treatment-induced immunosuppression. Vaccination represents a cornerstone of supportive care in oncology; however, vaccine uptake remains suboptimal and immune responses are frequently attenuated, particularly in patients with hematological malignancies and those receiving highly immunosuppressive therapies. This review provides a comprehensive synthesis of current evidence on vaccine immunogenicity, clinical effectiveness, and safety in oncology patients. We discuss immunological mechanisms underlying impaired vaccine responses, summarize evidence for major vaccines recommended in oncology practice, and address key clinical challenges such as timing relative to anticancer therapies, heterogeneity of immune responses, and vaccine hesitancy. An extended discussion highlights emerging strategies, including booster dosing, adjuvanted vaccines, and personalized vaccination approaches. Finally, future perspectives are outlined to improve integration of vaccination into routine oncology care.

Indexed as

cancerimmunocompromised hostimmunogenicityoncologypreventive oncologyvaccination

Identifiers

PMID41893787
PMCPMC13030256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.